The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A multi-institutional, single-arm, phase II trial of neoadjuvant modified-FOLFIRINOX for resectable pancreatic ductal adenocarcinoma.
 
Choong-kun Lee
Honoraria - Boryung; Dong-A ST; Novartis; SERVIER
Consulting or Advisory Role - AstraZeneca
 
Ho Kyoung Hwang
No Relationships to Disclose
 
Hei-Cheul Jeung
No Relationships to Disclose
 
Hongjae Chon
Consulting or Advisory Role - AstraZeneca; Bayer; BMS; Celgene Cancer Care Links/BMS; Eisai; Green Cross; Menarini; MSD Oncology; Ono Pharmaceutical; Roche; Sanofi; SERVIER; Sillajen
Speakers' Bureau - Bayer; BMS; Celgene/Bristol-Myers Squibb; Dong-A ST; Eisai; Menarini; Roche; Sanofi; SERVIER
Research Funding - Boryung (Inst); Dong-A ST (Inst); Roche (Inst)
 
Hyung Soon Park
No Relationships to Disclose
 
Min Hwan Kim
No Relationships to Disclose
 
Sung Hyun Kim
No Relationships to Disclose
 
Mi-Suk Park
No Relationships to Disclose
 
Chang Moo Kang
No Relationships to Disclose
 
Hye Jin Choi
No Relationships to Disclose